Skip to main content
. 2019 Nov 19;34(4):769–778. doi: 10.1111/jdv.16018

Figure 3.

Figure 3

Distribution of confounders between anti‐interleukin‐12/23 agent (ustekinumab) and tumour necrosis factor‐α inhibitors (referent) patients before creating propensity score and after overlap weighting by propensity score. (a) Outcomes occurring during drug therapy. (b) Outcomes occurring during drug therapy plus grace period (90 days).